UroGen Pharma Ltd.

NASDAQ:URGN

13.1 (USD) • At close September 18, 2024
Bedrijfsnaam UroGen Pharma Ltd.
Symbool URGN
Munteenheid USD
Prijs 13.1
Beurswaarde 551,694,710
Dividendpercentage 0%
52-weken bereik 10.6 - 20.7
Industrie Biotechnology
Sector Healthcare
CEO Ms. Elizabeth A. Barrett
Website https://www.urogen.com

An error occurred while fetching data.

Over UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102,

Vergelijkbare Aandelen

CVRx, Inc. logo

CVRx, Inc.

CVRX

8.69 USD

Annexon, Inc. logo

Annexon, Inc.

ANNX

6.93 USD

Checkpoint Therapeutics, Inc. logo

Checkpoint Therapeutics, Inc.

CKPT

2.46 USD

ChromaDex Corporation logo

ChromaDex Corporation

CDXC

3.55 USD

Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

HOWL

2.22 USD

Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc.

JSPR

22.74 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)